1.460USD+0.69%Mkt Cap: 32.46M USDP/E: —Last update: 2026-06-01
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940,…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap32.46M USD
Enterprise Value-11.99M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-58.20M USD
Revenue/Share—
Last Price1.460 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.13
PEG—
EV/EBITDA0.20
EV/Revenue—
P/S—
P/B0.38
EPS (TTM)-2.49
EPS (Forward)-1.28
52W Range
0.961069% of range1.680
52W High1.680 USD
52W Low0.9610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.99%
ROA-37.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.66M USD
CapEx (TTM)546.00K USD
FCF Margin—
FCF Yield-94.01%
Net Debt-44.56M USD
Net Debt/EBITDA0.75
Balance Sheet
Debt/Equity0.50
Current Ratio9.87
Quick Ratio9.69
Book Value/Sh3.855 USD
Cash/Share4.133 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.22.46M
Float15.33M
Insiders11.35%
Institutions49.77%
Short Interest
Short Ratio0.1d
Short % Float0.19%
Short % Out.0.12%
Shares Short25.99K
Short (prev mo.)145.15K
Technical
SMA 501.377 (+6.0%)
SMA 2001.244 (+17.4%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)122.96K
Avg Vol (10d)110.86K
Technical Indicators
RSI (14)49.5
MACD0.0079
MACD Signal0.0202
MACD Hist.-0.0122
BB Upper1.612 USD
BB Middle1.493 USD
BB Lower1.375 USD
BB Width15.83%
ATR (14)0.0771 USD
Vol Ratio (20d)0.27x